source
- Kamau Therapeutics presents first clinical data from its updated sickle-cell gene-editing programKamau Therapeutics, a biotech company that entered the scene in 2023, has released clinical data from its reengineered sickle‑cell gene‑editing program for the first time. The disclosure marks the…
- Pfizer raises 2026 outlook as oncology and migraine growth balances Covid product declinePfizer announced it has increased its financial guidance for 2026, citing stronger performance in its cancer and migraine divisions. The company said sales of its Covid-19 related products have fa…